New Alzheimer’s imaging approval could help unlock Lantheus’ neurology merger payouts

Lantheus Holdings has added another commercial asset to its neurology diagnostics portfolio at a particularly consequential moment for the company, with the United States Food and Drug Administration approving TAUKLARIFY for tau PET imaging in adults with cognitive impairment being evaluated for Alzheimer’s disease. The approval arrives less than two weeks after Curium agreed to acquire Lantheus Holdings in a transaction valued at up to approximately $8 billion, including contingent payments linked directly to the performance of Lantheus’ neurology diagnostics franchise. TAUKLARIFY, also known as florquinitau F 18 or MK-6240, is specifically included within the portfolio whose future sales can trigger those payments. That makes the product more than an incremental imaging approval because its eventual commercial performance could contribute to additional cash consideration for Lantheus Holdings shareholders after the proposed merger closes.

Curium has agreed to pay $102.50 per Lantheus Holdings share in cash at closing plus contingent value rights worth as much as another $12 per share if specified commercial milestones are achieved through 2030. Within those contingent rights, the global neurology diagnostics franchise can generate up to $3 per share, with a $2 payment if annual adjusted sales exceed $300 million and another $1 if they exceed $350 million during any of the fiscal years ending in 2028, 2029 or 2030. The definition explicitly covers Neuraceq, MK-6240 and other current or future radiodiagnostics containing florquinitau, making TAUKLARIFY potentially relevant to those thresholds.

TAUKLARIFY gives Lantheus another Alzheimer’s imaging product as neurology becomes strategically more valuable

TAUKLARIFY is an F18-labeled radiodiagnostic indicated for PET imaging of the brain to identify tau neurofibrillary tangle pathology in adults with cognitive impairment who are being evaluated for Alzheimer’s disease. The medicine is administered intravenously at an approximate activity of 185 megabecquerels before PET imaging, allowing trained readers to classify scans as positive or negative for clinically relevant tau pathology. The approval does not establish TAUKLARIFY as a standalone Alzheimer’s diagnostic, and its safety and effectiveness have not been established for evaluating tauopathies unrelated to Alzheimer’s disease.

The strategic significance lies in how TAUKLARIFY complements Lantheus Holdings’ existing neurology business. The company already markets Neuraceq, an amyloid PET imaging agent, and generated $39.6 million from Neuraceq during the second quarter of 2026. Adding a tau imaging product allows Lantheus Holdings to participate in assessment of two major pathological hallmarks associated with Alzheimer’s disease rather than relying primarily on amyloid imaging.

Amyloid and tau provide different information about the disease process, meaning the products do not necessarily compete with one another inside Lantheus Holdings’ portfolio. Lantheus Holdings said tau PET can complement amyloid PET and other diagnostic tools as clinicians and researchers seek a more complete understanding of Alzheimer’s disease. The company initially plans to continue using TAUKLARIFY through its Pharma Solutions business to support Alzheimer’s therapeutic-development programs while it evaluates the appropriate path toward broader commercial availability.

That measured launch strategy limits the likelihood that TAUKLARIFY immediately becomes a large revenue contributor. It also provides Lantheus Holdings with an opportunity to establish the tracer in pharmaceutical clinical trials, build relationships with Alzheimer’s drug developers and determine where tau PET adds the greatest value before committing to wider commercialization.

The timing could become increasingly favorable as Alzheimer’s treatment moves toward biomarker-driven patient selection and monitoring. Disease-modifying medicines and late-stage clinical programs have increased the importance of determining what pathology is present in the brain, although tau PET must compete with amyloid imaging, cerebrospinal-fluid testing and rapidly evolving blood-based biomarker technologies.

High reader agreement gives TAUKLARIFY a solid clinical foundation but early disease remains challenging

FDA approval was supported by two blinded image-read studies using PET scans from more than 500 subjects who had participated in three clinical trials. The population included cognitively unimpaired individuals as well as people with mild cognitive impairment and mild Alzheimer’s dementia, allowing investigators to examine performance across a broad cognitive spectrum.

Study 1 included images from 279 subjects. Positive percent agreement across independent readers ranged from 80% to 88%, while negative percent agreement ranged from 98% to 99%. Inter-reader consistency was high, producing a generalized Fleiss’ kappa of 0.92. Study 2 analyzed images from 338 subjects and produced positive percent agreement ranging from 68% to 82% and negative percent agreement of 93% to 99%, with a Fleiss’ kappa of 0.86.

Those findings indicate that trained readers can generally interpret TAUKLARIFY scans consistently, which is important commercially because an imaging agent whose results vary substantially from one reader to another would be difficult to integrate into routine diagnostic workflows.

The label nevertheless contains a meaningful limitation. TAUKLARIFY performance can be weaker in individuals at earlier stages of tau pathology, while neither a positive nor negative scan should be treated as definitive proof that clinically significant Alzheimer’s tau pathology is present or absent. Physicians may therefore need additional clinical or biomarker evidence when imaging results are uncertain.

Safety was evaluated in 1,734 subjects. Headache was reported in 0.7% of patients and nausea in 0.2%, while injection-site reactions, dizziness and abdominal discomfort each occurred in approximately 0.1%. TAUKLARIFY is a radioactive diagnostic agent, so its prescribing information also addresses radiation exposure and recommends procedures intended to reduce unnecessary exposure.

TAUKLARIFY enters an established tau PET market where differentiation will determine adoption

Lantheus Holdings is not creating the commercial tau PET category from scratch. TAUVID, or flortaucipir F 18, received FDA approval in 2020 for PET imaging of tau neurofibrillary tangles in adults with cognitive impairment being evaluated for Alzheimer’s disease. That gives physicians an established alternative and means TAUKLARIFY must compete on factors such as image characteristics, reader confidence, distribution, reimbursement and integration into pharmaceutical-development programs.

The existence of an incumbent could constrain rapid adoption, but Lantheus Holdings possesses commercial and manufacturing infrastructure that may help the product compete. The company already operates one of the largest radiopharmaceutical businesses in the United States and generated $388.2 million in worldwide revenue during the second quarter. Its existing products include prostate cancer imaging agent PYLARIFY, amyloid imaging agent Neuraceq and ultrasound enhancing agent DEFINITY.

Second-quarter PYLARIFY revenue was $240.4 million, Neuraceq generated $39.6 million and DEFINITY produced $88.3 million. Overall revenue increased 2.7% from the prior-year period to $388.2 million, while GAAP operating income rose 13.9% to $100.2 million. Cash and cash equivalents totaled $593.3 million at June 30.

Those numbers highlight why TAUKLARIFY does not need to become another PYLARIFY immediately to be strategically meaningful. Lantheus Holdings already has substantial commercial scale, allowing a new neurology diagnostic to develop alongside established products rather than carrying the financial burden of the company by itself.

TAUKLARIFY could also reinforce the strategic value Curium sees in Lantheus Holdings. Curium specifically identified Lantheus Holdings’ U.S. commercial infrastructure and diagnostic franchises as complementary to its own global radiopharmaceutical manufacturing and therapeutic capabilities. The combined company is expected to operate across oncology, neurology and cardiology and serve patients in more than 70 countries if the transaction closes as planned during the first half of 2027.

Curium’s neurology CVR gives TAUKLARIFY approval an unusual direct link to shareholder value

The merger structure creates a distinctive connection between TAUKLARIFY’s future performance and the eventual consideration received by current Lantheus Holdings shareholders. Curium will pay $102.50 per share in cash at closing, while non-transferable contingent value rights could provide another $12 per share if several product-franchise milestones are achieved.

Global neurology diagnostics account for up to $3 of that contingent consideration. The first $2 becomes payable if adjusted annual franchise sales exceed $300 million during any of 2028, 2029 or 2030, while another $1 becomes payable if sales exceed $350 million during one of those years. The defined portfolio includes Neuraceq, TAUKLARIFY’s development identifier MK-6240, NAV-4694, LNTH-2620 and current or future radiodiagnostics containing florbetaben, florquinitau, flutafuranol or PI-2620.

TAUKLARIFY therefore does not need to generate $300 million independently. Its sales can contribute alongside the rest of the defined global neurology portfolio toward the applicable milestone. Neuraceq’s existing revenue base gives that calculation a starting point, while commercial availability of TAUKLARIFY could add another contributor if uptake expands before the 2028-to-2030 measurement window.

The milestones remain far from guaranteed. Lantheus Holdings has not provided a commercial sales forecast for TAUKLARIFY, broad availability has not yet been launched and the Alzheimer’s diagnostic landscape could change substantially before 2028 as blood biomarkers become more accurate and accessible. The contingent value rights are specifically structured so no payment is owed unless the required thresholds are achieved.

Still, FDA approval removes the regulatory risk that TAUKLARIFY would never become a marketed contributor to the neurology portfolio. For shareholders evaluating the Curium transaction, that makes the neurology component of the CVR somewhat more tangible than it was before August 14, even though its eventual value remains dependent on commercialization.

LNTH stock trades close to Curium’s guaranteed cash price as investors discount the contingent upside

Lantheus Holdings shares were trading around $100.87 during the August 14 session, nearly unchanged from the previous close. The stock’s intraday range was approximately $100.85 to $101.39, while the company’s market capitalization stood near $6.81 billion.

The current price sits modestly below Curium’s $102.50 cash consideration due at closing and substantially below the theoretical maximum $114.50 value if every contingent milestone is achieved. That spread reflects the time remaining before closing, transaction risk and uncertainty over whether the contingent value rights will ever produce additional payments. This interpretation is an inference from the transaction structure and market price rather than a confirmed explanation from individual shareholders.

TAUKLARIFY approval did not meaningfully move Lantheus Holdings stock on Friday morning, which is understandable given the pending acquisition. Once a public company is trading primarily around agreed merger consideration, individual product announcements often have less immediate influence unless they materially change the probability of closing or the likely value of contingent payments.

TAUKLARIFY nevertheless matters more than Friday’s share-price reaction suggests. The product expands Lantheus Holdings’ Alzheimer’s imaging portfolio, adds another commercializable asset to the business Curium intends to acquire and directly enters the neurology franchise used to calculate as much as $3 per share of future CVR payments. The next question is no longer whether florquinitau can obtain FDA approval, but whether Lantheus Holdings and eventually Curium can turn that approval into enough clinical adoption and commercial revenue to make tau PET a meaningful part of the combined company’s neurology business.

Key takeaways on what TAUKLARIFY approval means for Lantheus Holdings and the Curium deal

• The FDA has approved TAUKLARIFY, or florquinitau F 18, for tau PET imaging in adults with cognitive impairment being evaluated for Alzheimer’s disease.
• TAUKLARIFY complements Lantheus Holdings’ existing Neuraceq amyloid PET franchise, potentially giving the company exposure to both major Alzheimer’s imaging biomarkers.
• Lantheus Holdings initially plans to support Alzheimer’s therapeutic-development programs with TAUKLARIFY while evaluating broader commercial availability.
• The approval was supported by more than 500 subjects in blinded read studies and a safety database containing 1,734 subjects.
• TAUKLARIFY enters an established market where TAUVID has already been FDA approved for tau PET imaging since 2020.
• Curium has agreed to acquire Lantheus Holdings for $102.50 per share in cash plus contingent value rights worth as much as another $12 per share.
• Global neurology diagnostics can account for as much as $3 per share of those contingent payments if annual sales exceed specified $300 million and $350 million thresholds.
• TAUKLARIFY is explicitly included in the defined neurology diagnostics franchise through MK-6240 and florquinitau-containing radiodiagnostics.
• Lantheus Holdings generated $39.6 million of second-quarter revenue from Neuraceq and $388.2 million of total worldwide revenue, giving TAUKLARIFY an established commercial infrastructure to build upon.
• LNTH shares remained near $100.87 after the approval, below Curium’s $102.50 guaranteed closing consideration and well below the maximum $114.50 potential deal value.